Clinical Trials Logo

Filter by:
NCT ID: NCT05862064 Recruiting - Clinical trials for TNBC - Triple-Negative Breast Cancer

PD-1 Combined With Adjuvant Chemotherapy and Antivascular Therapy Versus Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer

Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

This review will evaluate the efficacy, safety, and pharmacokinetics of SHR1210 (carrelizumab) compared with the antivascular drug famitinib in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with conventional chemotherapy regimens (dose-intensive epirubicin and cyclophosphamide, sequential paclitaxel, or EC-P) in patients with early-stage high-risk TNBC.

NCT ID: NCT05861895 Recruiting - Solid Tumors, Adult Clinical Trials

A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Start date: December 12, 2023
Phase: Phase 1
Study type: Interventional

HF158K1 is an investigational liposome form of doxorubicin hydrochloride, an anthracycline topoisomerase inhibitor, encapsulated by lipid membranes containing TL01, a HER2-directed Trastuzumab Fab fragment conjugated lipid.

NCT ID: NCT05861869 Enrolling by invitation - Clinical trials for Membranous Nephropathy - PLA2R Induced

Clinical Trial of PLA2R-IgG4 Detection Kit (Time-resolved Fluorescence Immunoassay)

Start date: May 4, 2023
Phase:
Study type: Observational

The goal of this observational clinical trial is to compare assessment reagents with clinical diagnostic criteria in patients with membranous nephropathy. The main questions it aims to answer are: - Evaluating the sensitivity and specificity of the test reagent in the diagnosis of membranous nephropathy. - Evaluating whether the clinical diagnostic performance of the test reagent meets the requirements for auxiliary diagnosis of membranous nephropathy. Participants will provide approximately 4ml of blood. Researchers will compare the levels of anti-PLA2RIgG4 in patients with membranous nephropathy and patients with other renal diseases,to see if there is a significant difference.

NCT ID: NCT05861830 Recruiting - Clinical trials for Advanced Breast Cancer

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Start date: May 15, 2023
Phase: Phase 3
Study type: Interventional

CDK4/6 inhibitors are currently the standard treatment for female breast cancer patients with HR+ tumors. However, there is no established standard treatment for patients who experience treatment failure with CDK4/6 inhibitors. The MAINTAIN study has shown clinical benefits by switching to Ribociclib and changing endocrine therapy after progression on CDK4/6 inhibitors. We hypothesize that combining Dalpiciclib with physician-selected endocrine therapy, following treatment failure with CDK4/6 inhibitors, would similarly lead to improved patient survival. In this study, 18F-FES PET/CT will be employed as a non-invasive alternative to biopsy techniques for evaluating the expression of ER in various systemic lesions of the patients.

NCT ID: NCT05861778 Completed - Clinical trials for Clear Cell Renal Cell Carcinoma

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

ZIRDOSE-CP
Start date: June 26, 2023
Phase: Phase 1
Study type: Interventional

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

NCT ID: NCT05861765 Recruiting - Radial Artery Spasm Clinical Trials

The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography

PASS
Start date: May 24, 2023
Phase: Phase 2
Study type: Interventional

Rationale:Papaverine is effective on radial artery spasm during transradial cerebral angiography. Purpose: This multicenter, randomized, placebo-controlled, double blind, phase 2b trial aims to investigate the effect and safety of papaverine in treating radial artery spasm during transradial cerebral angiography.

NCT ID: NCT05861674 Recruiting - Clinical trials for Chronic Hepatitis Delta Virus Infection

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Start date: June 16, 2023
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.

NCT ID: NCT05861635 Recruiting - Breast Cancer Clinical Trials

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Start date: February 1, 2023
Phase: Phase 4
Study type: Interventional

To evaluate the efficacy and safety of vidicizumab combined with tirelizumab in the treatment of early high-risk or locally advanced breast cancer with low HER2 expression

NCT ID: NCT05861557 Not yet recruiting - Clinical trials for Locally Advanced Head and Neck Squamous Cell Carcinoma

Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma

Start date: May 20, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II study. Twenty-three patients with locally advanced head and neck squamous cell carcinoma were planned to be enrolled to assess the efficacy and safety of neoadjuvant immunotherapy combined with radiotherapy.

NCT ID: NCT05861414 Completed - Depressive Symptoms Clinical Trials

Intervention Effect of Emotional Working Memory Training on University Students With Depressive Symptom

Start date: October 11, 2022
Phase: N/A
Study type: Interventional

Objective: To investigate the effects of emotional working memory training (EWM-T) on depressive symptoms and rumination among university students. Methods: The experimental group comprised 25 participants who underwent 21 days of emotional working memory training, which involved viewing a continuous stream of negative emotional face content on a grid and remembering the faces and locations presented on the grid. The control group consisted of 25 participants. The Beck Depression Inventory-II (BDI-II), the Chinese version of the Character-Digital Breadth Test, and the Ruminative Responses Scale (RRS) were used as the pre- and post-test indicators.